-
公开(公告)号:US11161819B2
公开(公告)日:2021-11-02
申请号:US16935565
申请日:2020-07-22
发明人: Gregory L. Adams , Jason M. Cox , John S. Debenham , Scott Edmondson , Eric J. Gilbert , Yan Guo , Yu Jiang , Hubert Josien , Hyunjin M. Kim , Ping Lan , Shouwu Miao , Christopher W. Plummer , Murali Rajagopalan , Unmesh Shah , Zhongxiang Sun , Quang T. Truong , Feroze Ujjainwalla , Francisco Velazquez , Srikanth Venkatraman , Takao Suzuki , Nengxue Wang
IPC分类号: C07D217/04 , C07D401/04 , C07D401/12 , C07D413/04 , C07D417/12 , C07D417/14 , C07D401/06 , C07D417/04 , A61K31/4725 , C07D417/06 , C07D217/22 , A61K45/06 , A61K31/472 , A61K9/48 , A61P3/04 , A61P3/06 , A61P3/10 , A61P29/00
摘要: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
-
公开(公告)号:US08987195B2
公开(公告)日:2015-03-24
申请号:US13960343
申请日:2013-08-06
发明人: Thomas Bara , Sathesh Bhat , Dipshikha Biswas , Linda Brockunier , Duane A. Burnett , Samuel Chackalamannil , Mariappan V. Chelliah , Austin Chen , Martin Clasby , Vince J. Colandrea , Zhuyan Guo , Yongxin Han , Charles Jayne , Hubert Josien , Karen Marcantonio , Shouwu Miao , Santhosh Neelamkavil , Patrick Pinto , Murali Rajagopalan , Unmesh Shah , Francisco Velazquez , Srikanth Venkatraman , Yan Xia
IPC分类号: A61K38/00 , C07K5/08 , A61K38/06 , A61K45/06 , C07D491/22 , C07D419/00
CPC分类号: C07K5/08 , A61K38/06 , A61K45/06 , C07D419/00 , C07D491/22
摘要: The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.
摘要翻译: 本发明涉及含有螺环状的丙型肝炎病毒(HCV)NS3蛋白酶抑制剂,这些化合物的用途,以及这些化合物的合成。
-
公开(公告)号:US20210069288A1
公开(公告)日:2021-03-11
申请号:US17005686
申请日:2020-08-28
发明人: Hubert Josien , Abbas Walji , Harold B. Wood , Fa-Xiang Ding , Jian Liu , Thomas Joseph Tucker , Michael Man-Chu Lo , Liangqin Guo
摘要: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
-
公开(公告)号:US09957219B2
公开(公告)日:2018-05-01
申请号:US15034189
申请日:2014-12-01
发明人: Thomas Bara , Harry R. Chobanian , Yan Guo , Hubert Josien , Michael Miller , Barbara Pio , Christopher W. Plummer , Cangming Yang , Dong Xiao
IPC分类号: C07C59/72 , A61K45/06 , A61K31/192 , A61K31/404 , A61K31/435 , C07D221/04 , C07D231/12 , C07D207/333 , C07D277/42 , C07D209/12 , A61K31/277 , A61K31/381 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/437 , A61K31/44 , C07C255/59 , C07D209/08 , C07D213/64 , C07D249/04 , C07D333/24 , C07D417/04 , C07D471/04
CPC分类号: C07C59/72 , A61K31/192 , A61K31/277 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/435 , A61K31/437 , A61K31/44 , A61K45/06 , C07C255/59 , C07C2601/02 , C07C2601/14 , C07C2602/06 , C07C2602/08 , C07D207/333 , C07D209/08 , C07D209/12 , C07D213/64 , C07D221/04 , C07D231/12 , C07D249/04 , C07D277/42 , C07D333/24 , C07D417/04 , C07D471/04 , A61K2300/00
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US09834563B2
公开(公告)日:2017-12-05
申请号:US15039607
申请日:2014-12-17
发明人: William K. Hagmann , Bing Li , Jason W. Szewczyk , Bowei Wang , Dann Parker , Timothy Blizzard , Hubert Josien , Purakkattle Biju , Harry Chobanian , Candido Gude , Ravi P. Nargund , Barbara Pio , Qun Dang , Linus S. Lin , Bin Hu , Mingxiang Cui , Zhengxia Chen , Meibi Dai , Zaihong Zhang , Ying Lv , Lili Tian
IPC分类号: A61K31/506 , C07D493/04 , A61K45/06 , C07D213/64 , A61K31/44 , C07D409/12 , A61K31/4436 , C07D401/04 , A61K31/4545 , C07D471/04 , A61K31/437 , C07D405/12 , A61K31/4433 , C07D401/12 , A61K31/4439 , A61K31/443 , C07D239/34 , A61K31/505 , C07D451/06 , A61K31/46 , C07D221/20 , A61K31/438 , C07D213/74 , C07D417/04
CPC分类号: C07D493/04 , A61K31/437 , A61K31/438 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/46 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/64 , C07D213/74 , C07D221/20 , C07D239/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D451/06 , C07D471/04
摘要: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US20200347020A1
公开(公告)日:2020-11-05
申请号:US16935565
申请日:2020-07-22
发明人: Gregory L. Adams , Jason M. Cox , John S. Debenham , Scott Edmondson , Eric J. Gilbert , Yan Guo , Yu Jiang , Hubert Josien , Hyunjin M. Kim , Ping Lan , Shouwu Miao , Christopher W. Plummer , Murali Rajagopalan , Unmesh Shah , Zhongxiang Sun , Quang T. Truong , Feroze Ujjainwalla , Francisco Velazquez , Srikanth Venkatraman , Takao Suzuki , Nengxue Wang
IPC分类号: C07D217/04 , C07D401/04 , C07D401/12 , C07D413/04 , C07D417/12 , C07D417/14 , C07D401/06 , C07D417/04 , A61K31/4725 , C07D417/06 , C07D217/22 , A61K45/06 , A61K31/472 , A61K9/48 , A61P3/04 , A61P3/06 , A61P3/10 , A61P29/00
摘要: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
-
公开(公告)号:US09527875B2
公开(公告)日:2016-12-27
申请号:US14418147
申请日:2013-07-31
发明人: William K. Hagmann , Ravi P. Nargund , Timothy A. Blizzard , Hubert Josien , Purakkattle Biju , Christopher W. Plummer , Qun Dang , Bing Li , Derun Li , Linus S. Lin , Mingxiang Cui , Bin Hu , Jinglai Hao , Zhengxia Chen
IPC分类号: C07D417/12 , A61K31/4353 , C07F9/58 , C07D401/14 , C07D221/16 , C07D401/12 , A61K31/435 , A61K31/444 , A61K45/06 , A61K31/4412 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/496 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/675 , C07D405/12 , C07D409/14
CPC分类号: C07F9/58 , A61K31/435 , A61K31/4412 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/496 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D221/16 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/14 , C07D417/12
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
摘要翻译: 结构式(I)的新型化合物及其药学上可接受的盐是G蛋白偶联受体40(GPR40)的激动剂,可用于治疗,预防和抑制G蛋白偶联受体 受体40.本发明的化合物可用于治疗2型糖尿病,以及通常与该疾病相关的病症,包括肥胖症和脂质疾病,例如混合或糖尿病性血脂异常,高脂血症,高胆固醇血症和 高甘油三酯血症
-
公开(公告)号:US20190161448A1
公开(公告)日:2019-05-30
申请号:US16096710
申请日:2017-05-19
发明人: Gregory L. Adams , Jason M. Cox , John S. Debenham , Scott Edmondson , Eric J. Gilbert , Yan Guo , Yu Jiang , Hubert Josien , Hyunjin M. Kim , Ping Lan , Shouwu Miao , Christopher W. Plummer , Murali Rajagopalan , Unmesh Shah , Zhongxiang Sun , Quang T. Truong , Feroze Ujjainwalla , Francisco Velazquez , Srikanth Venkatraman , Takao Suzuki , Nengxue Wang
IPC分类号: C07D217/04 , C07D401/12 , C07D401/04 , C07D401/06 , C07D417/04 , C07D417/14 , C07D417/12 , C07D413/04 , A61P3/10 , A61P3/06 , A61P3/04 , A61P29/00
摘要: The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
-
公开(公告)号:US10000454B2
公开(公告)日:2018-06-19
申请号:US15310488
申请日:2015-05-19
发明人: Tesfaye Biftu , Purakkattle Biju , Timothy A. Blizzard , Zhengxia Chen , Matthew J. Clements , Mingxiang Cui , Jessica L. Frie , William K. Hagmann , Bin Hu , Hubert Josien , Anilkumar G. Nair , Christopher W. Plummer , Cheng Zhu
IPC分类号: C07D221/16 , A61K31/435 , A61K31/444 , C07D401/12 , C07D405/12 , A61K31/192 , A61K31/438 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/538 , A61K31/55 , A61K45/06 , C07C61/39 , C07D215/14 , C07D401/04 , C07D413/12
CPC分类号: C07D221/16 , A61K31/192 , A61K31/366 , A61K31/397 , A61K31/435 , A61K31/438 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/4985 , A61K31/538 , A61K31/55 , A61K45/06 , C07C61/39 , C07C2602/08 , C07C2603/12 , C07D215/14 , C07D401/04 , C07D401/12 , C07D405/12 , C07D413/12 , A61K2300/00
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US09932311B2
公开(公告)日:2018-04-03
申请号:US15023124
申请日:2014-09-30
发明人: Tesfaye Biftu , Purakkattle Biju , Steven L. Colletti , Mingxiang Cui , William K. Hagmann , Bin Hu , Hubert Josien , Nam Fung Kar , Anilkumar Nair , Ravi Nargund , Donald M. Sperbeck , Cheng Zhu
IPC分类号: C07D221/16 , C07D401/12 , C07D405/12 , C07D405/14 , A61K31/435 , A61K31/444 , A61K45/06
CPC分类号: C07D221/16 , A61K31/435 , A61K31/444 , A61K45/06 , C07D401/12 , C07D405/12
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
-
-
-
-
-
-
-
-